Astria Therapeutics, Inc. (NASDAQ:ATXS) Short Interest Update

Astria Therapeutics, Inc. (NASDAQ:ATXS) saw a significant decline in short interest in the month of December. As of December 15th, there was short interest totalling 2,680,000 shares, a decline of 14.9% from the November 30th total of 3,150,000 shares. Based on an average daily volume of 329,100 shares, the days-to-cover ratio is currently 8.1 days. Approximately 5.6% of the company’s shares are short sold.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on ATXS. HC Wainwright reiterated a “buy” rating and set a $16.00 price target on shares of Astria Therapeutics in a report on Tuesday, December 10th. Oppenheimer increased their target price on shares of Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a research note on Thursday, November 14th. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $25.60.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of ATXS. FMR LLC increased its position in Astria Therapeutics by 29.2% during the third quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock worth $86,123,000 after buying an additional 1,767,714 shares in the last quarter. RA Capital Management L.P. grew its stake in shares of Astria Therapeutics by 1.2% in the third quarter. RA Capital Management L.P. now owns 5,105,213 shares of the biotechnology company’s stock valued at $56,208,000 after buying an additional 61,457 shares in the last quarter. Vestal Point Capital LP grew its holdings in Astria Therapeutics by 23.1% during the 3rd quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company’s stock valued at $44,040,000 after purchasing an additional 750,000 shares in the last quarter. Millennium Management LLC boosted its stake in shares of Astria Therapeutics by 13.5% during the 2nd quarter. Millennium Management LLC now owns 1,842,063 shares of the biotechnology company’s stock valued at $16,763,000 after buying an additional 218,518 shares during the last quarter. Finally, Affinity Asset Advisors LLC grew its holdings in Astria Therapeutics by 15.4% during the 2nd quarter. Affinity Asset Advisors LLC now owns 975,606 shares of the biotechnology company’s stock worth $8,878,000 after acquiring an additional 130,000 shares in the last quarter. 98.98% of the stock is currently owned by hedge funds and other institutional investors.

Astria Therapeutics Stock Down 2.9 %

ATXS traded down $0.27 during trading on Friday, hitting $9.15. 244,427 shares of the stock were exchanged, compared to its average volume of 586,688. The firm has a market capitalization of $516.37 million, a P/E ratio of -4.38 and a beta of 0.67. Astria Therapeutics has a 1-year low of $6.58 and a 1-year high of $16.90. The stock has a fifty day moving average price of $10.45 and a two-hundred day moving average price of $10.72.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.